ICCC vs. ABIO, AWH, VNRX, OCX, CDIO, TRIB, TKNO, OKYO, GANX, and HCWB
Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include ARCA biopharma (ABIO), Aspira Women's Health (AWH), VolitionRx (VNRX), OncoCyte (OCX), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Alpha Teknova (TKNO), OKYO Pharma (OKYO), Gain Therapeutics (GANX), and HCW Biologics (HCWB). These companies are all part of the "medical" sector.
ImmuCell (NASDAQ:ICCC) and ARCA biopharma (NASDAQ:ABIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability.
In the previous week, ImmuCell had 4 more articles in the media than ARCA biopharma. MarketBeat recorded 6 mentions for ImmuCell and 2 mentions for ARCA biopharma. ARCA biopharma's average media sentiment score of 0.45 beat ImmuCell's score of 0.16 indicating that ARCA biopharma is being referred to more favorably in the news media.
ARCA biopharma has a net margin of 0.00% compared to ImmuCell's net margin of -18.31%. ImmuCell's return on equity of -15.21% beat ARCA biopharma's return on equity.
13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 56.4% of ARCA biopharma shares are owned by institutional investors. 6.3% of ImmuCell shares are owned by insiders. Comparatively, 30.9% of ARCA biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
ARCA biopharma received 2 more outperform votes than ImmuCell when rated by MarketBeat users. However, 73.33% of users gave ImmuCell an outperform vote while only 42.27% of users gave ARCA biopharma an outperform vote.
ImmuCell has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, ARCA biopharma has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.
ARCA biopharma has lower revenue, but higher earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than ARCA biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
ARCA biopharma beats ImmuCell on 9 of the 14 factors compared between the two stocks.
Get ImmuCell News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuCell Competitors List
Related Companies and Tools
